Citizens Jmp Expects Lower Earnings for National Research

National Research Corporation (NASDAQ:NRC) – Investment analysts at Citizens Jmp dropped their FY2026 earnings estimates for National Research in a report released on Thursday, October 29th. Citizens Jmp analyst C. Davides now forecasts that the company will post earnings of $0.97 per share for the year, down from their prior forecast of $0.98. Citizens Jmp currently has a “Market Outperform” rating and a $27.00 target price on the stock. The consensus estimate for National Research’s current full-year earnings is $0.97 per share. Citizens Jmp also issued estimates for National Research’s Q4 2026 earnings at $0.24 EPS, Q1 2027 earnings at $0.23 EPS and FY2027 earnings at $1.06 EPS.

A number of other research analysts have also weighed in on NRC. Weiss Ratings raised National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Wall Street Zen downgraded National Research from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Zacks Research upgraded National Research to a “hold” rating in a research note on Monday, October 5th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, National Research currently has a consensus rating of “Hold” and a consensus target price of $27.00.

National Research Stock Up 1.8%

NRC stock opened at $24.26 on Monday. The company has a 50 day moving average price of $21.26 and a two-hundred day moving average price of $19.22. The company has a debt-to-equity ratio of 13.13, a quick ratio of 0.65 and a current ratio of 0.65. The stock has a market capitalization of $551.91 million, a P/E ratio of 86.65 and a beta of 0.25. National Research has a one year low of $11.73 and a one year high of $24.69.

National Research (NASDAQ:NRC) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.03. National Research had a net margin of 4.48% and a return on equity of 171.97%. The business had revenue of $38.40 million for the quarter, compared to the consensus estimate of $35.80 million.

Institutional Investors Weigh In On National Research

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRC. Heartland Advisors Inc. raised its holdings in National Research by 374.3% in the first quarter. Heartland Advisors Inc. now owns 237,147 shares of the company’s stock valued at $4,027,000 after buying an additional 187,147 shares during the period. Farmers & Merchants Investments Inc. lifted its position in National Research by 51.7% during the third quarter. Farmers & Merchants Investments Inc. now owns 501,731 shares of the company’s stock valued at $10,632,000 after buying an additional 171,082 shares in the last quarter. Fifth Third Bancorp acquired a new position in National Research during the first quarter valued at approximately $1,531,000. Integrity Alliance LLC. purchased a new stake in National Research during the third quarter worth approximately $538,000. Finally, Quantinno Capital Management LP grew its stake in National Research by 61.3% during the first quarter. Quantinno Capital Management LP now owns 62,329 shares of the company’s stock worth $1,058,000 after buying an additional 23,682 shares during the period. 47.26% of the stock is currently owned by institutional investors and hedge funds.

National Research Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 29th will be issued a $0.16 dividend. The ex-dividend date is Tuesday, December 29th. This represents a $0.64 dividend on an annualized basis and a yield of 2.6%. National Research’s dividend payout ratio (DPR) is presently 228.57%.

National Research Company Profile

National Research Corporation, formerly traded on the Nasdaq under the symbol NRC, provides research, analytics and performance-improvement services to the health care industry. Through its NRC Health business, the company helps hospitals, health systems and other care organizations understand and improve patient, consumer and employee experiences.

Its offerings have included patient and employee surveys, market research, reputation management, loyalty and engagement programs, benchmarking, and software tools that turn feedback and other data into operational insights.